🎉 M&A multiples are live!
Check it out!

Pyxis Oncology Valuation Multiples

Discover revenue and EBITDA valuation multiples for Pyxis Oncology and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Pyxis Oncology Overview

About Pyxis Oncology

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.


Founded

2018

HQ

United States of America
Employees

50

Financials

LTM Revenue $11.5M

LTM EBITDA n/a

EV

-$50.4M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Pyxis Oncology Financials

Pyxis Oncology has a last 12-month revenue of $11.5M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Pyxis Oncology achieved revenue of $16.1M and an EBITDA of -$65.5M.

Pyxis Oncology expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Pyxis Oncology valuation multiples based on analyst estimates

Pyxis Oncology P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $16.1M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$80.3M -$65.5M XXX XXX XXX
EBITDA Margin -Infinity% -406% XXX XXX XXX
Net Profit -$121M -$73.8M XXX XXX XXX
Net Margin -Infinity% -457% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Pyxis Oncology Stock Performance

As of April 15, 2025, Pyxis Oncology's stock price is $1.

Pyxis Oncology has current market cap of $56.4M, and EV of -$50.4M.

See Pyxis Oncology trading valuation data

Pyxis Oncology Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$50.4M $56.4M XXX XXX XXX XXX $-1.29

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Pyxis Oncology Valuation Multiples

As of April 15, 2025, Pyxis Oncology has market cap of $56.4M and EV of -$50.4M.

Pyxis Oncology's trades at -4.4x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Pyxis Oncology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Pyxis Oncology and 10K+ public comps

Pyxis Oncology Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$50.4M XXX XXX XXX
EV/Revenue -3.1x XXX XXX XXX
EV/EBITDA 0.8x XXX XXX XXX
P/E -0.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Pyxis Oncology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Pyxis Oncology Valuation Multiples

Pyxis Oncology's NTM/LTM revenue growth is -100%

Pyxis Oncology's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $1.7M for the same period.

Over next 12 months, Pyxis Oncology's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Pyxis Oncology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Pyxis Oncology and other 10K+ public comps

Pyxis Oncology Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -406% XXX XXX XXX XXX
EBITDA Growth -18% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $1.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 157% XXX XXX XXX XXX
R&D Expenses to Revenue 364% XXX XXX XXX XXX
Opex to Revenue 521% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Pyxis Oncology Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Pyxis Oncology M&A and Investment Activity

Pyxis Oncology acquired  XXX companies to date.

Last acquisition by Pyxis Oncology was  XXXXXXXX, XXXXX XXXXX XXXXXX . Pyxis Oncology acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Pyxis Oncology

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Pyxis Oncology

When was Pyxis Oncology founded? Pyxis Oncology was founded in 2018.
Where is Pyxis Oncology headquartered? Pyxis Oncology is headquartered in United States of America.
How many employees does Pyxis Oncology have? As of today, Pyxis Oncology has 50 employees.
Who is the CEO of Pyxis Oncology? Pyxis Oncology's CEO is Dr. Lara S. Sullivan, M.D..
Is Pyxis Oncology publicy listed? Yes, Pyxis Oncology is a public company listed on NAS.
What is the stock symbol of Pyxis Oncology? Pyxis Oncology trades under PYXS ticker.
When did Pyxis Oncology go public? Pyxis Oncology went public in 2021.
Who are competitors of Pyxis Oncology? Similar companies to Pyxis Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Pyxis Oncology? Pyxis Oncology's current market cap is $56.4M
What is the current revenue of Pyxis Oncology? Pyxis Oncology's last 12-month revenue is $11.5M.
What is the current EV/Revenue multiple of Pyxis Oncology? Current revenue multiple of Pyxis Oncology is -4.4x.
Is Pyxis Oncology profitable? Yes, Pyxis Oncology is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.